Dalcetrapib Phase IIb Trial HDL-C Increase at Week 12 *P <0.0001 vs placebo Change From Baseline (%) * * * placebo n = 73 dalcetrapib 300 mg n = 75 dalcetrapib 600 mg n = 67 dalcetrapib 900 mg n = 72 NOTE: Dalcetrapib 600 mg is the dose used in phase III Stein EA. Am J Cardiol. 2009;104:82-91.